Article Collection: Short- and Long-term Real-World Outcomes of Advanced Therapies for Inflammatory Bowel Disease (IBD)

This article collection, titled “Short- and Long-term Real-World Outcomes of Advanced Therapies for Inflammatory Bowel Disease (IBD)”, brings together key research focused on the effectiveness and practical outcomes of advanced treatments for IBD. Covering a range of therapies, the collection provides insights into both short- and long-term results observed in real-world clinical settings. Examining factors such as drug response, treatment discontinuation, and the use of generic options, these studies contribute valuable knowledge for the optimization of care in patients with IBD.

This collection was edited by Hiroshi Nakase (Sapporo Medical University School of Medicine, Sapporo, Japan) and Masanao Nakamura (Nagoya University, Nagoya, Japan), and published in the journal Inflammatory Intestinal Diseases.

Conflict of Interest statements

Hiroshi Nakase: Received personal fees from AbbVie, Daiichi Sankyo, EA Pharma, Gilead Sciences, Janssen Pharmaceutical K. K, JIMRO, Kissei Pharmaceutical, KYORIN Pharmaceutical, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, Pfizer Japan, Takeda Pharmaceutical, and Viatris; received grants for commissioned/joint research from AbbVie, Hoya Group Pentax Medical, Mitsubishi Tanabe Pharma, and Mochida Pharmaceutical; and has an endowed chair funded by JIMRO, KYORIN Pharmaceutical, Miyarisan Pharmaceutical, and Mochida Pharmaceutical.

Masanao Nakamura: Honoraria from AbbVie, EA Pharma, Janssen Pharmaceutical K. K, Mochida Pharmaceutical, Pfizer Japan, and Takeda Pharmaceutical.

Image: Thipphaphone – stock.adobe.com